Conestoga Capital Advisors LLC Has $121.51 Million Stake in Repligen Corporation $RGEN

Key Points

• Conestoga Capital Advisors LLC reduced its stake in Repligen Corporation by 0.3%, holding approximately $121.51 million worth of shares, making it the 26th largest holding in their portfolio.
• A notable insider transaction occurred when Director Martin D. Madaus purchased 1,800 shares at an average price of $112.13 each, increasing his ownership stake in the company.
• Repligen's stock has a current market cap of $8.59 billion, with a recent stock price of $152.60, following a quarterly earnings report that showed revenue growth but a slight earnings miss compared to analysts' expectations.

Conestoga Capital Advisors LLC trimmed its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 0.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 976,907 shares of the biotechnology company's stock after selling 3,340 shares during the period. Repligen accounts for about 1.8% of Conestoga Capital Advisors LLC's portfolio, making the stock its 26th biggest holding. Conestoga Capital Advisors LLC owned approximately 1.74% of Repligen worth $121,508,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in RGEN. Twin Tree Management LP acquired a new stake in shares of Repligen in the first quarter valued at approximately $29,000. Signaturefd LLC increased its stake in shares of Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 128 shares during the period. Center for Financial Planning Inc. increased its stake in shares of Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 193 shares during the period. GAMMA Investing LLC increased its stake in shares of Repligen by 40.1% during the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 274 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Repligen during the first quarter worth approximately $132,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Martin D. Madaus acquired 1,800 shares of the stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the purchase, the director directly owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Repligen Price Performance

Repligen stock opened at $152.60 on Monday. The stock's fifty day moving average price is $128.81 and its two-hundred day moving average price is $126.33. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm has a market cap of $8.59 billion, a PE ratio of -610.38, a price-to-earnings-growth ratio of 2.82 and a beta of 1.08.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same quarter last year, the business earned $0.40 EPS. Repligen's revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. HSBC assumed coverage on Repligen in a research note on Wednesday, October 1st. They set a "buy" rating and a $150.00 target price on the stock. Royal Bank Of Canada reiterated an "outperform" rating and set a $205.00 target price on shares of Repligen in a research note on Tuesday, September 2nd. Weiss Ratings reiterated a "sell (d)" rating on shares of Repligen in a research note on Wednesday, October 8th. Hsbc Global Res upgraded Repligen to a "strong-buy" rating in a research note on Wednesday, October 1st. Finally, Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research note on Sunday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average price target of $169.62.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.